The antitumor effects by targeting TIM-3 may be required under certain conditions; for example, in the cases of IFN-γ-producing CD8+ and CD4+ T cells and when the ratio of tumor-infiltrating CD8+:CD4+ T cells is high [131]. Here, CD4 is linked to neoplasm.